ABBV241129C177500
- 6.00
- +2.14+55.44%
AbbVie Newsroom
Why AbbVie Inc. (ABBV) Is One of the Most Undervalued Pot Stocks to Buy?
Express News | The world's first ovarian cancer ADC drug has been approved domestically.
Unusual Options Activity: EDR, BBD and Others Attract Market Bets, EDR V/OI Ratio Reaches 174.3
EST Nov 26th Closing Delivery - In the last three hours of trading, 10 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options
Alector/AbbVie-Partnered Alzheimer's Drug Disappoints In Mid-Stage Study; Alector Lays Off 17% Of Workforce
(ABBV) - Analyzing AbbVie's Short Interest
Is AbbVie Inc. (ABBV) the Best Dividend Aristocrat Stock To Buy Right Now?
JPMorgan Updates Its U.S. Analyst Focus List – Adds TPR, ALRM, REG
Market Whales and Their Recent Bets on ABBV Options
Capsida Biotherapeutics to Present at 7th Annual Evercore HealthCONx Conference
AbbVie to Present at Citi's 2024 Global Healthcare Conference
Are Hedge Funds Betting Big On AbbVie Inc. (ABBV)?
Trump Picks Surgeon Makary to Head FDA, Rep. Dave Weldon to Lead CDC
AbbVie Gains on Leerink Partners Upgrade to Outperform
On CNBC, Jim Lebenthal Announced Bought More AbbVie; Bought More Cisco Systems
AbbVie, Nvidia Lead Friday's Market Cap Stock Movers
This Elastic Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday
AbbVie Analyst Ratings
Leerink Partners Upgrades AbbVie(ABBV.US) to Buy Rating, Announces Target Price $206
Express News | Abbvie : Leerink Partners Raises to Outperform From Market Perform
Optimism Over Global Healthcare Sector Rises: Jefferies